Skip to content

Efficacy of Surgical Treatment of Osteomyelitis in Diabetic Foot Ulcers

Prospective Randomized Clinical Trial Comparing Efficacy Surgical Versus Medical Treatment of Osteomyelitis in Diabetic Foot Ulcers

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01137903
Enrollment
88
Registered
2010-06-07
Start date
2010-04-30
Completion date
2011-11-30
Last updated
2010-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteomyelitis, Diabetic Foot, Diabetic Foot Ulcers

Keywords

Diabetic foot, Osteomyelitis, Diabetic foot ulcers, Foot infections

Brief summary

Hypothesis:Surgical treatment of osteomyelitis in diabetic foot is more effective that medical treatment through antibiotherapy and leads wound healing in ulcers complicated with bone infection.Material and Methods: Randomized clinical trials which include two groups of patients (n=88), one receives medical treatment through antibiotherapy during 90 days and the other group receive conservative surgical treatment and antibiotics during 7 days after surgery. It will be studied differences between both groups in healing time, recidives, present and relationship of adverse events and outflow of quality of life related health .

Interventions

Osteotomy, phalangectomy, exostectomy, metatarsal head resection, articular resection, partial calcanectomy

DRUGCiprofloxacin

500 mg/ 12 hours during 90 days

875/125 mg/12 hours during 90 days

Trimethoprim 160 mg / Sulfamethoxazole 800 mg 1/12 horas.

Sponsors

Universidad Complutense de Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with Diabetes Mellitus Type 1 or 2. * Patients with diabetic foot ulcers. * Patients with clinical suspects of osteomyelitis. * Patients with positive probe to bone test. * Patients with signs of osteolysis in the bone located adjacent to the ulcer in X-Ray * Patients with transcutaneous oxygen oxygenation above 30 mmHg. * Acceptance to participate in the study through prior informed consent.

Exclusion criteria

* Patients with osteomyelitis associated with necrotizing soft tissue infections. * Presence of necrotic tissue in the wound bed, edges or margins of the lesion. * HbAc1 \> 10. * Presence of systemic toxicity such as fever, tachycardia, confusion, disorientation, vomiting or other signs usually related to systemic infection. * Patients with bone exposure through the ulcer. * Patients with absent pulses, ankle/brachial index (ABI) \<0.8 and TcPO2 \<30 mmHg. * Pregnancy. * Allergies to antibiotics. * Any degree of renal impairment that contraindicated the administration of antibiotics proposed. * Hepatic insufficiency. * Mental Illnesses that prevent the understanding by the patient's proposed treatment, or for any other reason associated with your mental health, to recommend their inclusion.

Design outcomes

Primary

MeasureTime frameDescription
Number of healing patients12 weeksNumber of diabetic foot ulcers healing in both arms.

Secondary

MeasureTime frameDescription
Reulceration1 year after healingAnalysis of re-ulceration events in both arms after healing in a 1 year follow-up
Healing time12 weeksHealing time in both arms
Complications12 weeksPercentage of complications in both arms
Quality of life12 weeksQuality of life related to health in both arms

Countries

Spain

Contacts

Primary ContactJosé Luis Lázaro Martínez, PhD
diabetes@enf.ucm.es+34913942203

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026